Navigation Links
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
Date:3/29/2009

isks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.



    CONTACT:  Paul Donovan
              +1-508-650-8541 (office)
              +1-508-667-5165 (mobile)
              Med
'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
3. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
4. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
5. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
6. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
7. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
8. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. Another LNA-based RNA Inhibitor Enters Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... LONDON , July 23, 2014  Lightlake ... developing addiction treatments based on its expertise in ... an investigational new drug application ("IND") with respect ... Lightlake also announced today that it has received ... Drug Abuse ("NIDA"), part of the National Institutes ...
(Date:7/23/2014)... , July 23, 2014  Silk Road ... the transcarotid treatment of intra- and extra-cranial cerebrovascular ... P. Wallace to the position of Chief ... lead the company,s Research and Development efforts across ... Prior to joining Silk Road ...
(Date:7/23/2014)... , July 23, 2014  ACON Equity Partners III, ... Investments, L.L.C. ("ACON") announced it has completed the purchase ... from Audax Group and Parthenon Capital Partners. IWP is ... billion Workers, Compensation, Automobile Personal Injury Protection and Personal ... . As part of this ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3ACON Investments Acquires Injured Workers Pharmacy 2ACON Investments Acquires Injured Workers Pharmacy 3
... Therapeutics, Inc. (Nasdaq: ECTE ), a company ... wireless, transdermal continuous glucose monitoring system and its Prelude® ... results for the year ended December 31, 2011.  Echo,s ... website at www.echotx.com . 2011 ...
...   Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... of senior vice president and chief commercial officer. Mr. Palekar ... activities. "Rohan has an outstanding track record of ... president and CEO of Avanir. "I am delighted that we ...
Cached Medicine Technology:Echo Therapeutics, Inc. Announces 2011 Financial Results 2Echo Therapeutics, Inc. Announces 2011 Financial Results 3Echo Therapeutics, Inc. Announces 2011 Financial Results 4Echo Therapeutics, Inc. Announces 2011 Financial Results 5Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 2Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 3
(Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
(Date:7/23/2014)... 23, 2014 (HealthDay News) --,Jealousy may not be the ... can get downright possessive when it comes to the ... affection toward what was actually a stuffed dog, the ... pushing the stuffed dog aside, report researchers from the ... streak only surfaced when owners were attending to the ...
(Date:7/23/2014)... research on human cancer genes have been focused on ... to be translated in the form of amino acids ... a regulatory region or activator which controls the expression ... little was known of the role exerted such DNA ... today in Nature in collaboration with the ...
(Date:7/23/2014)... County, NJ (PRWEB) July 23, 2014 ... is the first hospital in New Jersey to receive ... most advanced robotics platform in the da Vinci series. ... and a profound step forward in innovation. The intuitive ... used across a wide spectrum of minimally invasive and ...
(Date:7/23/2014)... Vancouver, BC (PRWEB) July 23, 2014 ... has recently announced the launch of its custom orthotics ... correcting and eliminating foot abnormalities in order to restore ... the joints and cause less fatigue and pain. In ... and reduced pressure in the foot, resulting in relief ...
Breaking Medicine News(10 mins):Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Dogs Can Get Jealous, Too 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2
... risk of obesity later in life, research suggests , ... during pregnancy reduces an infant,s birth weight, which may ... researchers say. , In a new study, 84 first-time ... groups, with those in the exercise group participating in ...
... ... Laboratory Notebook) to be fully supported on the revolutionary Apple iPad. , ... (PRWEB) April 5, 2010 -- Amphora Research ... supported on the revolutionary Apple iPad., , ,"Science often happens in places where using a ...
... ... today. This newly launched initiative from MedPage Today, the online daily breaking medical news ... and critical thinkers while preserving their editorial independence. , ... Little Falls, New Jersey (PRWEB) April 5, 2010 ...
... finds relationships often founder after failed pregnancy, , MONDAY, April ... when she miscarried at 14 weeks. That she was already ... understand was that having my other children and realizing how ... who lives in Highland Ranch, Colo. , At first, her ...
... ... Day on April 7th, Swanson Health Products will donate five percent of the day,s sales ... ... Health Products plans to donate five percent of sales from Wednesday, April 7th, to Vitamin ...
... ... Expanded Its Free Webinars to Cover New Obama Health Reform ... Insurance Reimbursement Checks Directly with Valid Assignment and Nondiscrimination Protections ... and Individual Health Plan to Accept Patient Assignment to Send ...
Cached Medicine News:Health News:Expectant Mom's Exercise Keeps Newborn's Birth Weight Down 2Health News:Amphora's PatentSafe Electronic Laboratory Notebook Fully Supported on the Apple iPad 2Health News:MedPage Today Launches New Related SitesTM Initiative with KevinMD.com as First Collaborator 2Health News:MedPage Today Launches New Related SitesTM Initiative with KevinMD.com as First Collaborator 3Health News:For Many Couples, Toll of Miscarriage Lingers 2Health News:For Many Couples, Toll of Miscarriage Lingers 3Health News:For Many Couples, Toll of Miscarriage Lingers 4Health News:Swanson Health Products to Make Donation for Haiti Relief Efforts 2Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 2Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 3Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 4Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 5
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: